NASDAQ:SLRN Acelyrin (SLRN) Stock Price, News & Analysis → Like Tiny Crypto Retirement Funds (From Crypto 101 Media) (Ad) Free SLRN Stock Alerts $7.62 -0.22 (-2.81%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$7.15▼$7.7350-Day Range$5.90▼$8.6352-Week Range$5.70▼$29.88Volume955,580 shsAverage Volume1.18 million shsMarket Capitalization$741.73 millionP/E RatioN/ADividend YieldN/APrice Target$23.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Acelyrin alerts: Email Address Acelyrin MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside210.6% Upside$23.67 Price TargetShort InterestBearish11.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 7 Articles This WeekInsider TradingSelling Shares$198,548 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($7.40) to ($4.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.94 out of 5 starsMedical Sector659th out of 947 stocksPharmaceutical Preparations Industry308th out of 435 stocks 3.3 Analyst's Opinion Consensus RatingAcelyrin has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.67, Acelyrin has a forecasted upside of 210.6% from its current price of $7.62.Amount of Analyst CoverageAcelyrin has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.49% of the float of Acelyrin has been sold short.Short Interest Ratio / Days to CoverAcelyrin has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Acelyrin has recently increased by 3.59%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAcelyrin does not currently pay a dividend.Dividend GrowthAcelyrin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLRN. Previous Next 3.2 News and Social Media Coverage News SentimentAcelyrin has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Acelyrin this week, compared to 3 articles on an average week.Search Interest10 people have searched for SLRN on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows2 people have added Acelyrin to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acelyrin insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $198,548.00 in company stock.Percentage Held by Institutions94.68% of the stock of Acelyrin is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acelyrin are expected to grow in the coming year, from ($7.40) to ($4.24) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyMy next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign up About Acelyrin Stock (NASDAQ:SLRN)Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.Read More SLRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLRN Stock News HeadlinesMarch 18, 2024 | finance.yahoo.comSLRN Apr 2024 2.500 putMarch 13, 2024 | americanbankingnews.comAcelyrin (NASDAQ:SLRN) Shares Gap Up to $7.48March 18, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 12, 2024 | seekingalpha.comAcelyrin: Analyzing Its Recovery And Potential In Psoriatic ArthritisMarch 12, 2024 | markets.businessinsider.comHold Rating Affirmed for ACELYRIN, INC. as Izokibep Faces Competitive Hurdles and Safety ConcernsMarch 11, 2024 | marketwatch.comAcelyrin Stock Climbs 10% on Positive Results for Arthritis TreatmentMarch 11, 2024 | msn.comAcelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis StudyMarch 11, 2024 | markets.businessinsider.comAcelyrin's Phase2b/3 Trial Of Izokibep In Psoriatic Arthritis Meets Primary EndpointMarch 18, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 11, 2024 | globenewswire.comACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic ArthritisMarch 11, 2024 | globenewswire.comACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for PatientsFebruary 15, 2024 | finance.yahoo.comACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate CommunicationsFebruary 15, 2024 | globenewswire.comACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate CommunicationsFebruary 9, 2024 | markets.businessinsider.comHold Rating on ACELYRIN, INC. Amidst Clinical Trials and Risk/Reward AnalysisJanuary 16, 2024 | markets.businessinsider.comAcelyrin Final Deadline AlertJanuary 12, 2024 | stockhouse.comUpcoming SLRN Deadline: Bronstein, Gewirtz & Grossman LLC Reminds ACELYRIN, Inc. Investors with Substantial Losses to Contact the Firm!January 12, 2024 | stockhouse.comDEADLINE MONDAY ALERT: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses of $100,000 to Contact the FirmJanuary 11, 2024 | stockhouse.comMONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses of $100,000 to Contact the FirmJanuary 11, 2024 | stockhouse.com4-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the FirmJanuary 10, 2024 | markets.businessinsider.comSLRN DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Acelyrin, Inc. (SLRN) Securities Fraud Class Action LawsuitJanuary 10, 2024 | stockhouse.comMONDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses of $100,000 to Contact the FirmJanuary 7, 2024 | markets.businessinsider.comImportant January 16, 2024 Deadline Reminder for Acelyrin, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of Securities Fraud Class Action LawsuitJanuary 5, 2024 | stockhouse.comSLRN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds ACELYRIN, Inc. Investors with Substantial Losses to Contact the Firm!January 5, 2024 | markets.businessinsider.comAcelyrin (SLRN) Faces Investor Fraud Lawsuit for Allegedly Lying About Drug Candidate's Progress-Hagens BermanJanuary 3, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) InvestorsJanuary 3, 2024 | morningstar.comAcelyrin (SLRN) Faces Investor Fraud Lawsuit for Allegedly Lying About Drug Candidate’s Progress-Hagens BermanJanuary 2, 2024 | stockhouse.comAcelyrin Deadline ReminderSee More Headlines Receive SLRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acelyrin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/18/2024Next Earnings (Estimated)3/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SLRN CUSIPN/A CIK1962918 Webwww.acelyrin.com Phone805-730-0360FaxN/AEmployees108Year FoundedN/APrice Target and Rating Average Stock Price Target$23.67 High Stock Price Target$68.00 Low Stock Price Target$8.00 Potential Upside/Downside+210.6%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.94% Return on Assets-32.52% Debt Debt-to-Equity RatioN/A Current Ratio11.89 Quick Ratio11.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares97,340,000Free FloatN/AMarket Cap$741.73 million OptionableOptionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Shao-Lee Lin M.D. (Age 57)Ph.D., Co-Founder, CEO & Director Comp: $846.25kMs. Melanie Gloria B.S.N. (Age 46)Chief Operating Officer Comp: $672.58kMr. Gilbert M. Labrucherie J.D. (Age 52)Chief Financial Officer, Principal Financial Officer & principal accounting officer Ms. Mina Kim (Age 50)Chief Legal & Administrative Officer Mr. Tyler MarciniakHead of Investor Relations & CommunicationsMr. Ron Oyston (Age 54)Chief People Officer Dr. Paul M. Peloso M.D. (Age 66)M.Sc., Chief Medical Officer Ms. Suzy Buckhalter CPASenior Director of Finance & AccountingMr. Kenneth A. Lock (Age 50)Chief Commercial Officer Dr. Shephard Mpofu M.D.Senior Vice President of DevelopmentMore ExecutivesKey CompetitorsTyra BiosciencesNASDAQ:TYRAZymeworksNYSE:ZYMEPharvarisNASDAQ:PHVSWave Life SciencesNASDAQ:WVECureVacNASDAQ:CVACView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 2,966,883 shares on 3/11/2024Ownership: 6.324%Goldman Sachs Group Inc.Sold 660,914 shares on 3/1/2024Ownership: 1.149%Shao-Lee LinSold 15,701 sharesTotal: $119,327.60 ($7.60/share)Virtus ETF Advisers LLCBought 12,717 shares on 2/15/2024Ownership: 0.013%Bridgefront Capital LLCBought 11,249 shares on 2/15/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions SLRN Stock Analysis - Frequently Asked Questions Should I buy or sell Acelyrin stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acelyrin in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SLRN shares. View SLRN analyst ratings or view top-rated stocks. What is Acelyrin's stock price target for 2024? 7 equities research analysts have issued 1 year price objectives for Acelyrin's stock. Their SLRN share price targets range from $8.00 to $68.00. On average, they expect the company's share price to reach $23.67 in the next year. This suggests a possible upside of 210.6% from the stock's current price. View analysts price targets for SLRN or view top-rated stocks among Wall Street analysts. How have SLRN shares performed in 2024? Acelyrin's stock was trading at $7.46 at the beginning of the year. Since then, SLRN stock has increased by 2.1% and is now trading at $7.62. View the best growth stocks for 2024 here. When is Acelyrin's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024. View our SLRN earnings forecast. What ETF holds Acelyrin's stock? Innovator IBD Breakout Opportunities ETF holds 12,128 shares of SLRN stock, representing 2.31% of its portfolio. When did Acelyrin IPO? (SLRN) raised $540 million in an IPO on Friday, May 5th 2023. The company issued 30,000,000 shares at a price of $18.00 per share. Who are Acelyrin's major shareholders? Acelyrin's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.32%), Vanguard Group Inc. (6.32%), Blue Owl Capital Holdings LP (2.36%), Decheng Capital LLC (1.41%), Goldman Sachs Group Inc. (1.15%) and Goldman Sachs Group Inc. (1.15%). Insiders that own company stock include Beth C Seidenberg, Biopartners Fund Ii Westlake, Mardi Dier, Ronald Oyston and Shao-Lee Lin. View institutional ownership trends. How do I buy shares of Acelyrin? Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLRN) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetryThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.